ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the first patient enrolled in a Phase 1 investigator sponsored trial (IST), named rESPECT, of its lead product eryaspase for the first-line treatment of pancreatic cancer. 

Menu